Bryan Johnson rebranded Blueprint as Immortals Rx and added GLP-1 microdoses, NAD+, peptides, and SGLT2 inhibitors to the platform. Here's what the new stack contains and what the evidence behind each addition actually says.
Bryan Johnson's post announcing the Immortals Rx rebrand racked up hundreds of thousands of views in 48 hours. The core message: his Blueprint platform is expanding from a strict supplement and lifestyle protocol into a full compounded medication service — with microdosed GLP-1s (semaglutide, tirzepatide), direct NAD+ infusion, peptides, SGLT2 inhibitors (Jardiance, Brenzavvy), estradiol, glutathione, and hair/skin complexes now available alongside the existing Blueprint supplements.
It is easy to dismiss the announcement as product marketing. But the underlying science for several of the new additions is serious, and the move signals something important: longevity medicine is becoming a consumer category. Here is what the new stack actually contains, what the evidence says, and what you can access without a prescription.
Blueprint launched as a personal experiment: Johnson spending over $2 million per year to test whether his biological age could be reversed through ruthless optimization of sleep, diet, exercise, and supplementation. The original supplement list was relatively conventional — omega-3, creatine, NMN, vitamin D, spermidine, lycopene, astaxanthin — backed by solid human evidence.
Immortals Rx expands the model to include compounded pharmaceuticals, making prescription compounds accessible through telemedicine. The platform appears to be targeting the gap between what longevity physicians know works and what most people can actually access. The viral response suggests he identified a real demand: people who want the same interventions that physicians like Peter Attia and David Sinclair discuss, but without finding a specialist who will prescribe them.
Microdosed GLP-1s (semaglutide / tirzepatide): GLP-1 agonists were developed for type 2 diabetes, then found to produce significant weight loss, and are now being investigated for cardiovascular, renal, and potentially longevity benefits. The cardiovascular outcome trials (LEADER for semaglutide, SURPASS-CVOT for tirzepatide) show 14–20% reductions in MACE events in high-risk populations. Whether metabolically healthy individuals benefit proportionally is unknown. Microdosing specifically — much lower than weight-loss doses — is not yet validated in RCTs. Prescription required.
NAD+ (direct IV / oral): NAD+ levels fall roughly 50% between age 20 and 60, and multiple cellular aging mechanisms (sirtuin activation, PARP repair, mitochondrial biogenesis) depend on adequate NAD+. NMN and NR are the most studied oral NAD+ precursors with published human bioavailability data. Direct NAD+ IV delivers higher plasma peaks but has a shorter elevation window. A 2023 study in *Nature Aging* confirmed NMN raises blood NAD+ by ~38% in 30 days at 500 mg/day. NMN supplements are available OTC and represent the most accessible entry point.
Peptides (BPC-157, thymalin, skin/sex complexes): Peptides vary enormously in evidence quality. BPC-157 has strong animal data for tissue repair and gut healing; human trials are limited. Thymalin (thymic peptides) has Soviet-era Russian data showing immune reconstitution in aging; Western replication is sparse. Skin and sex peptides (PT-141 for libido, GHK-Cu for collagen) have early human data in specific indications. Most require compounding pharmacies or research-grade sources.
SGLT2 inhibitors (Jardiance / Brenzavvy): These glucose-lowering drugs work by making kidneys excrete excess glucose. Beyond glucose control, they show 25–35% reductions in cardiovascular death and heart failure hospitalization in outcome trials. The ITP longevity trial of canagliflozin (same class) extended lifespan in male mice by ~14%. Prescription required.
Glutathione: Glutathione is the body's master antioxidant. IV glutathione peaks quickly and falls; sublingual and liposomal oral forms show more sustained elevation. GlyNAC (glycine + N-acetylcysteine) is the evidence-backed OTC approach to raising glutathione sustainably — a 2023 Baylor trial showed GlyNAC supplementation reversed multiple aging hallmarks in healthy older adults.
The pharmaceutical components of Immortals Rx require a physician. But several of the most evidence-backed additions are available without a prescription and represent the core of the Blueprint supplement protocol:
As an Amazon Associate, Stacking Years earns from qualifying purchases.
500–1000 mg/day in the morning, fasted or with water
Pharmaceutical-grade NMN (β-nicotinamide mononucleotide). The 2023 Nature Aging trial used 500 mg/day oral NMN and confirmed a 38% increase in blood NAD+ at 30 days. ProHealth uses HPLC purity verification; 1000 mg capsules allow flexible dosing. The most direct OTC route to raising NAD+ without prescription.
Rating: 4.6/5
View on Amazon · Affiliate link
500 mg/day, morning; increase to 1000 mg if well tolerated
Third-party tested NMN at 500 mg per capsule. NSF-registered facility, HPLC-confirmed purity. At 500 mg/day, NMN has demonstrated NAD+ elevation in multiple small human trials. Competitive pricing for sustained daily supplementation.
Rating: 4.5/5
View on Amazon · Affiliate link
300 mg/day (double to 600 mg if using as primary NAD+ strategy)
The most clinically studied NAD+ precursor with 8+ human RCTs confirming blood NAD+ elevation by 40–60% at 300–1000 mg/day. NR and NMN raise NAD+ via different enzymatic pathways; NR is slightly better studied in humans, NMN may produce higher peak levels per milligram.
Rating: 4.7/5
View on Amazon · Affiliate link
Bryan Johnson's Immortals Rx represents the logical next step for the Blueprint protocol: moving from supplements (available to anyone) to pharmaceuticals (requiring medical supervision). The core OTC supplements — NMN or NR for NAD+ restoration, creatine for muscle, omega-3 for cardiovascular and brain health, vitamin D/K2 for bone and immune function — remain the foundation, and the evidence base for these is solid.
The pharmaceutical additions (GLP-1s, SGLT2 inhibitors) are genuinely interesting from a longevity standpoint, but they require appropriate medical oversight, monitoring, and a risk-benefit analysis that accounts for your individual health status. The Immortals Rx model of telemedicine access is an attempt to make that access more equitable — whether it executes on that vision remains to be seen.